Current challenges in treating MRSA: what are the options?

NV Ratnaraja, Peter Hawkey

Research output: Contribution to journalArticle

13 Citations (Scopus)


This review looks at the challenges facing the worldwide community with the increasing problem of methicillin resistance in Staphylococcus aureus. The epidemiology and natural history of community-associated methicillin-resistant Staphylococcus aureus and the challenge of control is discussed. Options for treatment and review of key antimicrobial agents acting against methicillin-resistant S. aureus, both currently in use and in development, are addressed. There are a number of new agents, the place of which in therapeutic regimens is yet to emerge. The review attempts to inform the reader of the probable position of these agents.
Original languageEnglish
Pages (from-to)601-18
Number of pages18
JournalExpert Review of Anticancer Therapy
Issue number5
Publication statusPublished - 1 Oct 2008


  • iclaprim
  • tigecycline
  • linezolid
  • ceftobiprole
  • quinupristin-dalfopristin
  • dalbavancin
  • telavancin
  • ceftaroline
  • methicillin-resistant S. aureus treatment
  • daptomycin
  • tomopenem
  • community-associated methicillin-resistant Staphylococcus aureus
  • oritavancin


Dive into the research topics of 'Current challenges in treating MRSA: what are the options?'. Together they form a unique fingerprint.

Cite this